ATE272842T1 - Diagnose spongiformer encephalopathie - Google Patents

Diagnose spongiformer encephalopathie

Info

Publication number
ATE272842T1
ATE272842T1 AT97909428T AT97909428T ATE272842T1 AT E272842 T1 ATE272842 T1 AT E272842T1 AT 97909428 T AT97909428 T AT 97909428T AT 97909428 T AT97909428 T AT 97909428T AT E272842 T1 ATE272842 T1 AT E272842T1
Authority
AT
Austria
Prior art keywords
spongiform encephalopathy
diagnosis
bse
animal
typing
Prior art date
Application number
AT97909428T
Other languages
English (en)
Inventor
John Collinge
Original Assignee
D Gen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26310231&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE272842(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9621469.7A external-priority patent/GB9621469D0/en
Priority claimed from GBGB9621885.4A external-priority patent/GB9621885D0/en
Application filed by D Gen Ltd filed Critical D Gen Ltd
Application granted granted Critical
Publication of ATE272842T1 publication Critical patent/ATE272842T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
AT97909428T 1996-10-15 1997-10-15 Diagnose spongiformer encephalopathie ATE272842T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9621469.7A GB9621469D0 (en) 1996-10-15 1996-10-15 Diagnosis
GBGB9621885.4A GB9621885D0 (en) 1996-10-21 1996-10-21 Diagnosis
PCT/GB1997/002843 WO1998016834A1 (en) 1996-10-15 1997-10-15 Diagnosis of spongiform encephalopathy

Publications (1)

Publication Number Publication Date
ATE272842T1 true ATE272842T1 (de) 2004-08-15

Family

ID=26310231

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97909428T ATE272842T1 (de) 1996-10-15 1997-10-15 Diagnose spongiformer encephalopathie

Country Status (10)

Country Link
US (1) US6998231B2 (de)
EP (1) EP0934531B1 (de)
JP (1) JP2001503141A (de)
AT (1) ATE272842T1 (de)
AU (1) AU4711597A (de)
CA (1) CA2268904A1 (de)
DE (2) DE69730142T2 (de)
ES (1) ES2134749T3 (de)
NZ (1) NZ335290A (de)
WO (1) WO1998016834A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617119B2 (en) 1997-02-21 2003-09-09 The Regents Of The University Of California Assay for specific strains of multiple disease related conformations of a protein
US6221614B1 (en) 1997-02-21 2001-04-24 The Regents Of The University Of California Removal of prions from blood, plasma and other liquids
US6620629B1 (en) 1997-02-21 2003-09-16 The Regents Of The University Of California Method for detecting prions
AT407160B (de) * 1998-06-04 2001-01-25 Immuno Ag Verfahren zur bestimmung von antigenen
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
GB9908059D0 (en) * 1999-04-09 1999-06-02 Imp College Innovations Ltd Diagnosis and treatment of diseases
RS51523B (sr) * 2000-07-07 2011-06-30 Laboratoires Serono Sa. Rana dijagnoza konformacionih bolesti
GB2376071A (en) * 2001-05-31 2002-12-04 Mini Agriculture & Fisheries Method for typing a TSE strain
GB0119339D0 (en) * 2001-08-08 2001-10-03 Medical Res Council Method
GB0125606D0 (en) * 2001-10-25 2001-12-19 Sec Dep For Environment Food & Diagnostic method
GB0227651D0 (en) * 2002-11-27 2003-01-08 Medical Res Council Prion
EP1774015A4 (de) * 2004-07-09 2009-01-21 Chronix Biomedical Inc Nachweis von nukleinsäuren zur beurteilung des risikos von bse (bovine spongiform encephalopathy)
DK2040548T3 (da) * 2006-06-23 2012-08-13 Amicus Therapeutics Inc Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase
WO2010019270A1 (en) 2008-08-14 2010-02-18 Isis Pharmaceuticals, Inc. Modulation of prion expression
US12281305B2 (en) 2018-11-21 2025-04-22 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing prion expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892814A (en) 1987-06-22 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Method for distinguishing Creutzfeldt-Jakob disease from other dementias
GB9117910D0 (en) * 1991-08-20 1991-10-09 Nat Res Dev Oligonucleotides and their use in an assay
US5908969A (en) 1994-05-13 1999-06-01 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
US5565186A (en) * 1994-05-13 1996-10-15 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
US6008435A (en) * 1994-05-13 1999-12-28 The Regents Of The University Of California Detecting cow, sheep and human prions in a sample and transgenic mice used for same
US5789655A (en) 1994-05-13 1998-08-04 The Regents Of The University Of California Transgenic animals expressing artificial epitope-tagged proteins
EP0795132A1 (de) 1994-11-29 1997-09-17 The Minister Of Agriculture Fisheries And Food In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain Spongiforme encephalopathie nachweissverfahren
EP1416280A3 (de) * 1995-09-14 2005-08-10 The Regents of the University of California Antikörper spezifisch für natives PrPsc

Also Published As

Publication number Publication date
EP0934531A1 (de) 1999-08-11
CA2268904A1 (en) 1998-04-23
ES2134749T3 (es) 2005-03-16
US20020081645A1 (en) 2002-06-27
EP0934531B1 (de) 2004-08-04
ES2134749T1 (es) 1999-10-16
US6998231B2 (en) 2006-02-14
JP2001503141A (ja) 2001-03-06
DE69730142T2 (de) 2005-08-11
DE69730142D1 (en) 2004-09-09
NZ335290A (en) 2001-08-31
DE934531T1 (de) 2000-04-06
AU4711597A (en) 1998-05-11
WO1998016834A1 (en) 1998-04-23

Similar Documents

Publication Publication Date Title
DE69730142D1 (en) Diagnose spongiformer encephalopathie
CY1121645T1 (el) Διαγνωση και θεραπεια των προκαλουμενων με αντισωμα φλεγμονωδων αυτοανοσων διαταραχων
BRPI0112262B8 (pt) processo para detecção e teste para um marcador de uma doença conformacional, kit, processo para identificar um composto, processo para detectar a presença de uma forma patogênica prp sc de proteína de príon, e aparelho
DE69729473D1 (de) Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems
ATE440536T1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
DE69738739D1 (de) Verfahren für das Entwerfen von kleinen Erythropoietin Mimetika
ATE443147T1 (de) Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung
NO920125L (no) Fremgangsmaate for aa bestemme den funksjonelle aktivitetentil fritt protein s eller protein c i en plasmaproeve
ES2179324T3 (es) Un metodo de deteccion de las encefalopatias espongiformes transmisibles.
DE69821246D1 (de) Testverfahren für collagenpeptid
EP1543331A4 (de) Verfahren zur diagnose von morbus alzheimer
BR0010007A (pt) Indicadores biológicos para validação de um processo de esterilização de prìon
DE69841804D1 (de) Diagnoseverfahren
PT909388E (pt) Ensaios imunologicos para encefalopatias espongiformes
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
GB2333362A (en) Diagnosis of spongiform encephalopathy
ATE415632T1 (de) Verfahren zur diagnose und behandlung von morbus crohn
FR2849205B1 (fr) Procede d'amplification de la detection de la prpsc et utilisation d'un ligand adjuvant macrocyclique pour une telle amplification
DE60231106D1 (en) Test für übertragbare spongiforme encephalopathien
BR0111975A (pt) Fator, composição, veìculo, ligando, kits de diagnósticos, processos para detectar uma prpsc em uma amostra, e para remover prpsc de material biológico, método para diagnosticar encefalopatias espongiformes humanas transmissìveis e encefalopatias de prìons de animais, e, uso de um fator
BRPI0512948A (pt) biomarcadores de mal de alzheimer
EA199800352A1 (ru) ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА
Lezmi et al. CNA42 monoclonal antibody identifies FDC as PrPsc accumulating cells in the spleen of scrapie affected sheep
DE69940906D1 (de) Verfahren zur untersuchung von krankheiten des zentralen nervensystems und verfahren zum aufsuchen von arzneimitteln
DE69734890D1 (de) Rdgb-proteine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0934531

Country of ref document: EP

REN Ceased due to non-payment of the annual fee